SLDB
Income statement / Annual
Last year (2023), Solid Biosciences Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Solid Biosciences Inc.'s net income was -$96.02 M.
See Solid Biosciences Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00
|
$8.09 M
|
$13.62 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$76.56 M |
$2.41 M |
$58.74 M |
$3.92 M |
$2.82 M |
$1.57 M |
$448,000.00 |
$56,000.00 |
$0.00 |
| Gross Profit |
-$76.56 M |
$5.69 M |
-$45.12 M |
-$3.92 M |
-$2.82 M |
-$1.57 M |
-$448,000.00 |
-$56,000.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0.7 |
-3.31 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$76.56 M
|
$78.42 M
|
$58.74 M
|
$64.88 M
|
$94.74 M
|
$57.97 M
|
$39.91 M
|
$20.12 M
|
$4.19 M
|
| General & Administrative
Expenses |
$27.75 M
|
$28.95 M
|
$27.14 M
|
$21.58 M
|
$24.58 M
|
$17.72 M
|
$14.95 M
|
$5.46 M
|
$2.37 M
|
| Selling & Marketing
Expenses |
-$2.58 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$27.75 M
|
$28.95 M
|
$27.14 M
|
$21.58 M
|
$24.58 M
|
$17.72 M
|
$14.95 M
|
$5.46 M
|
$2.37 M
|
| Other Expenses |
$0.00 |
-$381,000.00 |
$2,000.00 |
$1.94 M |
$515,000.00 |
$270,000.00 |
$1.46 M |
$1.43 M |
-$103,000.00 |
| Operating Expenses |
$26.59 M |
$107.37 M |
$85.87 M |
$86.46 M |
$119.32 M |
$75.69 M |
$54.86 M |
$25.58 M |
$6.56 M |
| Cost And Expenses |
$103.16 M |
$107.37 M |
$85.87 M |
$86.46 M |
$119.32 M |
$75.69 M |
$54.86 M |
$25.58 M |
$6.56 M |
| Interest Income |
$7.14 M |
$2.62 M |
$64,000.00 |
$115,000.00 |
$1.58 M |
$619,000.00 |
$219,000.00 |
$369,000.00 |
$3,000.00 |
| Interest Expense |
$0.00 |
-$20.47 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$2.58 M
|
$2.41 M
|
$2.96 M
|
$3.92 M
|
$2.82 M
|
$1.57 M
|
$448,000.00
|
$56,000.00
|
$6.56 M
|
| EBITDA |
-$101.73 M
|
-$107.92 M
|
-$69.29 M
|
-$80.60 M
|
-$116.49 M
|
-$75.69 M
|
-$54.41 M
|
-$25.52 M
|
-$6.56 M
|
| EBITDA Ratio |
0 |
-13.33 |
-5.09 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
-13.15
|
-5.3
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$8.30 M
|
$20.47 M
|
$66,000.00
|
$116,000.00
|
$2.10 M
|
$270,000.00
|
$1.46 M
|
$1.43 M
|
-$103,000.00
|
| Income Before Tax |
-$96.02 M |
-$85.98 M |
-$72.19 M |
-$88.29 M |
-$117.22 M |
-$74.80 M |
-$53.18 M |
-$23.77 M |
-$6.66 M |
| Income Before Tax Ratio
|
0
|
-10.62
|
-5.3
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$20.47 M |
-$64,000.00 |
$1.83 M |
-$1.58 M |
$889,000.00 |
-$1.28 M |
-$2.60 M |
-$287,000.00 |
| Net Income |
-$96.02 M |
-$65.51 M |
-$72.12 M |
-$90.12 M |
-$115.64 M |
-$74.80 M |
-$52.12 M |
-$21.54 M |
-$6.38 M |
| Net Income Ratio |
0 |
-8.09 |
-5.3 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-4.83 |
-7.7 |
-10.13 |
-26.03 |
-43.05 |
-33.73 |
-24.26 |
-16.8 |
-4.97 |
| EPS Diluted |
-4.83 |
-7.7 |
-10.13 |
-26.03 |
-43.05 |
-33.73 |
-24.26 |
-16.8 |
-4.97 |
| Weighted Average Shares
Out |
$19.88 M
|
$8.51 M
|
$7.12 M
|
$3.46 M
|
$2.69 M
|
$2.22 M
|
$2.15 M
|
$1.28 M
|
$1.28 M
|
| Weighted Average Shares
Out Diluted |
$19.88 M
|
$8.51 M
|
$7.12 M
|
$3.46 M
|
$2.69 M
|
$2.22 M
|
$2.15 M
|
$1.28 M
|
$1.28 M
|
| Link |
|
|
|
|
|
|
|
|
|
